Results 131 to 140 of about 24,552 (280)

Pharmacokinetic Drug–Drug Interaction Potential of Oral Anticancer Drugs

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1614-1627, June 2026.
Drug–drug interaction (DDI) management is critical for safe and effective use of oral anticancer drugs (OADs). Our study objectives were to (i) compile clinically relevant pharmacokinetic (PK) DDI mechanisms for OADs and (ii) assess the prevalence of PK potential DDIs (PDDIs) in patients with advanced solid cancers.
Fatimah Alhurayri, Islam R. Younis, Shadia I. Jalal, Theodore F. Logan, Rohan Maniar, Steven M. Bray, Sara K. Quinney, Zeruesenay Desta, Todd C. Skaar, James E. Tisdale, Tyler Shugg   +10 more
wiley   +1 more source

Tüskés Gábor: Hagyomány és kritika, Könyvek, könyvbírálatok a kora újkori európai irodalom és művelődés történetéhez. Budapest, MTA BTK, 2013, 279 l. [PDF]

, 2015
István Monok
openalex  

Candidate compounds from the design of covalent Bruton's tyrosine kinase (BTK) inhibitors via focused deep generative modeling

, 2022
Atsushi Yoshimori, Filip Miljković, Jürgen Bajorath   +2 more
openalex   +2 more sources

Bruton tyrosine kinase (BTK) may be a potential therapeutic target for interstitial cystitis/bladder pain syndrome [PDF]

, 2022
Guang Wang, Tongxin Yang, Jiongming Li, Zi-Ye Huang, Wenbo Yang, Pei Li, Dalin He   +6 more
openalex   +1 more source

Recurrent Genomic Alterations in BCRi‐Experienced CLL Patients Treated With Venetoclax: Extended Phase 2 Follow‐Up

American Journal of Hematology, Volume 101, Issue 7, Page 1516-1521, July 2026.
Jennifer A. Woyach, Relja Popovic, Emily L. Rossi, Sanjana Singh, Toshihiko Oki, Tanya S. Rosenberg, Chen Qian, Michael Moran, Zihuan Liu, Michelle Boyer, Jeffrey Jones, Richard R. Furman, William Wierda, Jason Gotlib, Stephen J. Schuster, Brenda Chyla, Matthew S. Davids   +16 more
wiley   +1 more source

IGLV3‐21R110 and ibrutinib treatment: Results from the double‐blind, randomized, placebo‐controlled GCLLSG CLL12 trial in early‐stage CLL

HemaSphere, Volume 10, Issue 6, June 2026.
Abstract IGLV3‐21R110 is a point mutation enabling autonomous B‐cell receptor (BCR) signaling in chronic lymphocytic leukemia (CLL). It has been associated with shorter time to first treatment and overall survival, but its effects have not been evaluated in phase 3 clinical trials or in patients treated with Bruton tyrosine kinase inhibitors.
Deyan Y. Yosifov, Sandra Robrecht, Adam Giza, Palash C. Maity, Armin Riecke, Christof Schneider, Billy M. C. Jebaraj, Rashmi P. Dheenadayalan, Hassan Jumaa, Marc Young, Manish Kumar, Lothar Müller, Ursula Vehling‐Kaiser, Michael Eckart, Werner Freier, Björn Schöttker, Tobias Gaska, Marcel Reiser, Anna‐Maria Fink, Kirsten Fischer, Barbara Eichhorst, Michael Hallek, Petra Langerbeins, Eugen Tausch, Stephan Stilgenbauer   +24 more
wiley   +1 more source

A magyar gazdaság mozgatórugói a középkorban. Az MTA BTK „Lendület” Középkori Magyar Gazdaságtörténet Kutatócsoport hároméves (2015–2018) beszámolója [PDF]

, 2019
Boglárka Weisz
openalex  

Proof of concept of NX‐2127, a first‐in‐class Bruton's Tyrosine Kinase (BTK) dual‐targeted protein degrader with immunomodulatory activity, in patients with DLBCL [PDF]

, 2023
Alexey V. Danilov, Krish Patel, Weiyun Z. Ai, Michael Wang, Clare Sun, Philip O’Connor, A. Schwab, M. Tan, Adrian Wiestner   +8 more
openalex   +1 more source

Phase 3 PERSPECTIVE study: Ibrutinib with rituximab for initial treatment of patients with follicular lymphoma

HemaSphere, Volume 10, Issue 6, June 2026.
Abstract We report primary analysis results from the Phase 3 PERSPECTIVE study comparing ibrutinib + rituximab versus placebo + rituximab in patients with previously untreated follicular lymphoma requiring treatment per Groupe d'Etude des Lymphomes Folliculaires criteria who were ineligible for chemoimmunotherapy due to age and/or comorbidities.
David Belada, Faithlore P. Gardner, Ana C. de Oliveira, Juan‐Manuel Sancho, Elza Lomaia, David Wright, Mehmet Turgut, Elena Martynova, Zsolt Lázár, Bertrand Anz, Ming‐Chung Wang, Wojciech Legiec, Stephen Opat, Junvie Pailden, Hillary M. Peltier, Emerenziana Marturano, James P. Dean, Ian W. Flinn   +17 more
wiley   +1 more source

Btk inhibition treats TLR7/IFN driven murine lupus

, 2016
Andrew T. Bender, Albertina Pereira, Kai Fu, Eileen T. Samy, Yin Wu, Lesley Liu‐Bujalski, Richard D. Caldwell, Yi‐Ying Chen, Hui Tian, Federica Morandi, Jared Head, Ursula Koehler, Melinda Genest, Shinji L. Okitsu, Daigen Xu, Roland Grenningloh   +15 more
openalex   +1 more source